Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)

P-379: Outcomes of Multiple Myeloma Patients Relapsing After Upfront Autologous Stem Cell Transplant in a Brazilian Public Center: Real-World Data

P-380: Carfilzomib Dosing in Multiple Myeloma: An International Survey of Oncologist Practices

P-381: Talquetamab Utilization Patterns and Dose Schedules in the United States: A Real-World Analysis

P-382: IXAZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS – REAL WORLD EVIDENCE – EXPERIENCES OF THE CROATIAN COOPERATIVE GROUP FOR HEMATOLOGIC DISEASES (KROHEM)

P-383: Novel selinexor triplet and quadruplet regimens (SNd, SPEd, SBd, SDPd): Results from the Phase 1b/2 STOMP multiple myeloma trial

P-386: Effect of Prior Selinexor Exposure on Clinical Outcomes of Chimeric Antigen Receptor T-cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Descriptive Analysis

P-387: Pulmonary Complications in Plasma Cell Dyscrasia: A Case Series Highlighting Clinical Challenges and Management Strategies

P-389: Phase 3, two-stage, randomized trials of mezigdomide-based regimens versus standard regimens in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-1 (MeziVd vs PVd) and SUCCESSOR-2 (MeziKd vs Kd)

P-392: A Phase 1 Trial of 225Actinium-DOTA-Daratumumab in Patients with Daratumumab-refractory Multiple Myeloma: Results from First Cohorts

P-394: Selinexor combined with bortezomib, thalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients who have undergone severe treatment: a single-arm, multicenter, prospective study

P-395: Updated results from DREAMM-3, a phase 3 study of belantamab mafodotin (Belamaf) versus pomalidomide plus dexamethasone in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

P-396: Characterization and management of ocular events in patients (pts) treated with belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd) in the DREAMM-7 study

P-397: Brazilian Single-Center Initial Experience and Safety of Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma

P-398: Real-world Effectiveness of Ixazomib, Lenalidomide, and Dexamethasone (IRd) in Asian Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

P-400: A Discrete Choice Experiment analysis to understand Treatment Preferences of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) in the United States

P-401: Real-world experience with talquetamab clinical management in relapsed refractory multiple myeloma (RRMM): A qualitative study of US healthcare providers

P-402: Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM): an updated analysis based on 14-month follow-up data

P-403: Indirect comparison of linvoseltamab versus selinexor plus dexamethasone for penta-exposed relapsed/refractory multiple myeloma (RRMM)

P-405: EXCALIBER-RRMM: A phase 3, two-stage trial of iberdomide, daratumumab, dexamethasone (IberDd) versus daratumumab, bortezomib, dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma

P-407: Real-world outcomes in patients with relapsed-refractory multiple myeloma (RRMM) with prior proteasome inhibitor and lenalidomide exposure in Sweden

P-408: Survival Analysis of Selinexor-Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Real-World Exploratory Analysis

P-409: Real-Life Outcomes in Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Carfilzomib- and/or Pomalidomide-Based Regimens in the LocoMMotion and MoMMent Studies

P-410: ALLG MM26/D1/AMN009 Novel Combinations for Orphan Myeloma (NORM) Platform Study

P-413: Characterization and management of ocular events in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone in the DREAMM-8 study

P-415: Indirect comparison of linvoseltamab versus talquetamab for triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)

P-416: A MULTICENTER OBSERVATIONAL RETROSPECTIVE STUDY OF SECOND-LINE TREATMENT WITH DARATUMUMAB – BORTEZOMIB - DEXAMETHASONE (DaraVd) IN MULTIPLE MYELOMA (MM) PATIENTS REFRACTORY TO LENALIDOMIDE

P-417: Efficacy of Belantamab Mafodotin + Bortezomib + Dexamethasone (BVd) Compared to Alternative Regimens in 2L+ Relapsed/Refractory Multiple Myeloma (RRMM): A Network Meta-analysis of Randomized Trials

P-418: Subcutaneous administration of isatuximab by an on-body delivery system (OBDS) in multiple myeloma patients: results of a nurse survey

P-421: Characteristics of Patients and Management of Ocular Adverse Events After Treatment With Belantamab Mafodotin (Belamaf) in Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Study in Europe

P-422: Carfilzomib, Lenalidomide and Dexamethasone (KRD) therapy post autologous stem-cell transplantation (ASCT): real-world data in multiple myeloma patients eligible for second ASCT.